Quantum BioPharma (QNTM)
Develops clinical-stage treatments while retaining investments and consumer-product economics.
Quantum Biopharma (QNTM) Projected to Post Quarterly Earnings on Thursday
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) is anticipated to announce its results before the market opens on Thursday, August 6th. Analysts expect Quantum Biopharma to announce earnings of ($0.4116) per share for the quarter. Quantum Biopharma Stock Down 5.9% NASDAQ QNTM opened at $2.87 on Wednesday. The firm has a market cap of $18.37
Quantum BioPharma Announces Intention to Settle Debt
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates: The Company announces that its board of directors has approved the settlement of CAD$123,487.
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research
Quantum BioPharma stock momentum surges as MS study hits 50% enrollment and early PET imaging data shows promising results.
Comparing Quantum Biopharma (NASDAQ:QNTM) & Arcutis Biotherapeutics (NASDAQ:ARQT)
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) and Arcutis Biotherapeutics (NASDAQ: ARQT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Profitability This table compares Quantum Biopharma and Arcutis
Quantum Biopharma (QNTM) to Release Earnings on Friday
Quantum Biopharma (NASDAQ: QNTM - Get Free Report) is anticipated to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Quantum Biopharma Stock Down 1.7% QNTM stock opened at $2.36 on Friday. The stock has a market cap of $9.02
Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors
LOS ANGELES, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the "Class Period").
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group
TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today issued a formal response to the press releases published by The Schall Law Firm and DJS Law Group on October 9th and 10th , 2025, which announced an investigation into alleged securities law violations by the Company.
QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $QNTM--QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm.
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada.
Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript
Call Start: 16:30 January 1, 0000 4:57 PM ET Quantum BioPharma Ltd. (NASDAQ:QNTM ) Business Update Conference Call May 6, 2025, 04:30 PM ET Company Participants Zeeshan Saeed - Founder, Chief Executive Officer, President and Executive Co-Chair Jason Sawyer - Head of Finance and M&A Conference Call Participants Operator Greetings, and welcome to the Quantum BioPharma Business Update Conference Call.
Overlooked Stock: QNTM
Quantum's in the name but has no part of the business. Quantum BioPharma (QNTM) is up over 130% year to date but has fallen more than 50% off its all-time high.
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders TORONTO, ON / ACCESSWIRE / October 21, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces the Company, on 20th October 2024, has filed a complaint in the United States District Court for the Southern District of New York alleging that CIBC World Markets (CIBC), RBC Dominion Securities (RBC), and others (the "Defendants") engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.
QUANTUM BIOPHAR (QNTM) Upgraded to Buy: Here's What You Should Know
QUANTUM BIOPHAR (QNTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).